Imaging Breast Cancer with Fluorocholine PETMR to Predict Tumor Types and Outcomes A Study on Women Aged 25 to 75 Receiving Chemotherapy or Surgery

What this Trial Is About

This research aims to explore the use of pre-treatment Fluorocholine FCH PETMR imaging in women diagnosed with breast cancer. The study evaluates whether conventional PETMR imaging markers and advanced radiomic features, including deep learning analysis, are associated with different molecular subtypes of breast cancer, treatment response, clinical outcomes, and survival. The goal is to identify which imaging parameters are most accurate for predicting these factors. Participants will undergo two main imaging procedures before treatment whole-body PETMR using Fluorodeoxyglucose FDG and breast PETMR using Fluorocholine FCH. The whole-body PETMR follows a fasting period and involves an intravenous injection of FDG, followed by a 20-25 minute scan. The breast PETMR also requires fasting, an intravenous injection of FCH, a rest period, and then a 30-35 minute scan with MRI contrast media. These imaging tests occur on separate days with at least a two-day gap. Radiologists and nuclear medicine physicians analyze the results to provide information for clinical care. Participants are women aged 25 to 75 with a recent breast cancer diagnosis who will receive neoadjuvant chemotherapy or surgery. During the study, various imaging markers related to breast cancer subtypes and clinical outcomes are measured and compared. The primary outcome is the association between FCH PETMR parameters and breast cancer molecular subtypes, with follow-up lasting at least 40 weeks. Secondary outcomes include links to histologic grade and prognosis. Radiation exposure is monitored and is comparable to routine chest CT scans, with safety considerations in place throughout the study period.

Fluorocholine PET/MR in Breast Cancer